Lisata Therapeutics’ (LSTA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA) in a report issued on Thursday morning,Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock.

Lisata Therapeutics Stock Performance

Shares of LSTA stock opened at $2.88 on Thursday. Lisata Therapeutics has a 52-week low of $2.05 and a 52-week high of $3.83. The stock has a market cap of $24.16 million, a price-to-earnings ratio of -1.15 and a beta of 1.22. The firm’s 50-day moving average is $2.93 and its 200-day moving average is $3.09.

Lisata Therapeutics (NASDAQ:LSTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.16. During the same period in the prior year, the business posted ($0.65) earnings per share. Sell-side analysts predict that Lisata Therapeutics will post -2.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP boosted its stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 17,336 shares of the company’s stock after buying an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.